Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Organon (OGN) concluded the recent trading session at $20.18, signifying a +1.05% move from its prior day's close.

Analyst Terence Flynn of Morgan Stanley maintained a Hold rating on Organon (OGN – Research Report), retaining the price target of ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Barclays analyst Balaji Prasad maintained a Buy rating on Organon (OGN – Research Report) today and set a price target of $26.00. The ...

With its latest acquisition, women’s health outfit Organon is bringing its dermatology business to the U.S. with a potential ...

However, Organon was down 1.4%. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease. The FDA is also ...

Organon & Co (OGN) stock saw a decline, ending the day at $19.97 which represents a decrease of $-0.58 or -2.82% from the prior close of $20.55. The stock opened at $20.51 and touched a low of $19.42 ...

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an ...